These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16118859)

  • 1. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Sherry JH; Bechtel T
    Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16118859
    [No Abstract]   [Full Text] [Related]  

  • 2. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Perron R
    Neurology; 2005 Apr; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15858865
    [No Abstract]   [Full Text] [Related]  

  • 3. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Rackley RJ
    Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16118860
    [No Abstract]   [Full Text] [Related]  

  • 4. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Stetz SA
    Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16118861
    [No Abstract]   [Full Text] [Related]  

  • 5. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Jefferys RJ
    Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16116145
    [No Abstract]   [Full Text] [Related]  

  • 6. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Wiberg CC
    Neurology; 2005 Apr; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15851759
    [No Abstract]   [Full Text] [Related]  

  • 7. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Burkhardt RT; Leppik IE; Blesi K; Scott S; Gapany SR; Cloyd JC
    Neurology; 2004 Oct; 63(8):1494-6. PubMed ID: 15505173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes associated with brand-to-generic phenytoin interchange.
    Kinikar SA; Delate T; Menaker-Wiener CM; Bentley WH
    Ann Pharmacother; 2012 May; 46(5):650-8. PubMed ID: 22550275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More on high-dose busulfan and seizure prophylaxis.
    Tiberghien P; Flesch M; Paintaud G; Cahn JY
    Bone Marrow Transplant; 1992 Feb; 9(2):147. PubMed ID: 1637404
    [No Abstract]   [Full Text] [Related]  

  • 10. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
    Berg MJ; Gross RA; Tomaszewski KJ; Zingaro WM; Haskins LS
    Neurology; 2008 Aug; 71(7):525-30. PubMed ID: 18695164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
    Deleu D; Aarons L; Ahmed IA
    Arch Med Res; 2005; 36(1):49-53. PubMed ID: 15777995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical seizures in phenytoin toxicity.
    Chua HC; Venketasubramanian N; Tan CB; Tjia H
    Singapore Med J; 1999 Apr; 40(4):276-7. PubMed ID: 10487084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic anticonvulsant use in children: do we have evidence to recommend brand formulations?
    Hamiwka LD
    Arch Neurol; 2009 Nov; 66(11):1417-8. PubMed ID: 19901177
    [No Abstract]   [Full Text] [Related]  

  • 14. The value of specifying brand-name antiepileptic drugs.
    Ng YT
    Arch Neurol; 2009 Nov; 66(11):1415-6. PubMed ID: 19901176
    [No Abstract]   [Full Text] [Related]  

  • 15. Fosphenytoin facts.
    Chioffi SM; Lassiter TF; Scates AC; McLendon BM
    Am J Nurs; 1999 Aug; 99(8):14. PubMed ID: 10456012
    [No Abstract]   [Full Text] [Related]  

  • 16. Benefits of a clinical pharmacokinetic service in optimising phenytoin use in the western Cape.
    Valodia P; Seymour MA; Kies BM; Folb PI
    S Afr Med J; 1998 Jul; 88(7):873-5. PubMed ID: 9698715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is bioavailability altered in generic versus brand anticonvulsants?
    Jankovic SM; Ignjatovic Ristic D
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):329-32. PubMed ID: 25440299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dilantin jeopardy: avoiding the dangers of phenytoin.
    Schlicher ML
    Medsurg Nurs; 1998 Dec; 7(6):343-7, 356. PubMed ID: 10036438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of anticonvulsant levels in epileptics. I. Serum diphenylhydantoin concentrations in a group of medically indigent outpatients.
    Haerer AF; Grace JB
    Acta Neurol Scand; 1969; 45(1):18-31. PubMed ID: 4979531
    [No Abstract]   [Full Text] [Related]  

  • 20. Generic substitution in the treatment of epilepsy: patient and physician perceptions.
    Berg MJ; Gross RA; Haskins LS; Zingaro WM; Tomaszewski KJ
    Epilepsy Behav; 2008 Nov; 13(4):693-9. PubMed ID: 18589000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.